A Phase II Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimer's Disease
|Biohaven Pharmaceuticals, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Betina Idnay, RN: 212-342-5615 / firstname.lastname@example.org
T2 Protect AD is a clinical trial testing the investigational drug troriluzole in people with mild to moderate Alzheimer's disease (AD). The study is designed to determine whether this new drug can protect against, slow down, or potentially improve memory and thinking problems that increase as Alzheimer's disease progresses.
This study is closed
Karen Bell, MD
|Are you between the ages of 50-85?
|Do you have a diagnosis of Alzheimer's Disease (AD)?